<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327428</url>
  </required_header>
  <id_info>
    <org_study_id>Register Sichelzellkrankheit</org_study_id>
    <nct_id>NCT03327428</nct_id>
  </id_info>
  <brief_title>Sickle-cell Disease Registry of the GPOH</brief_title>
  <acronym>SichReg</acronym>
  <official_title>Register Sichelzellkrankheit Der GPOH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GPOH-Konsortium Sichelzellkrankheit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kliniken der Stadt Köln gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Tumor Diseases, Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Kinderkrebsstiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease is one of the most common hereditary diseases. Most severe complications
      can be avoided if the disease is detected early and treated appropriately.

      The sickle cell disease registry of the Society for Paediatric Oncology/Haematology aims at
      describing the epidemiology of sickle cell disease in German-speaking central Europe.
      Patients with sickle cell disease will be characterized clinically and genetically and
      treatment will be documented with the aim to find predictors of the course of disease.

      In addition, the registry results should provide a solid evidence base to incorporate sickle
      cell disease into routine newborn screening and to update the national guidelines for the
      management of patients suffering from sickle cell disease in Germany.

      A consortium of five university hospitals (Berlin, Frankfurt, Hamburg, Heidelberg, Ulm) has
      been mandated by the Society for Paediatric Oncology/Haematology to implement this registry.

      The number of participating centers is constantly increasing and new centers that take care
      of either pediatric or adult patients with sickle cell disease are encouraged to support the
      registry.

      For further information please refer to: http://www.sichelzellkrankheit.info/
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2040</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Change in incidence of sickle-cell disease</measure>
    <time_frame>Baseline and yearly, up to 10 years</time_frame>
    <description>The incidence of sickle-cell disease will be reported every year in comparison to the preceding Report.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of sickle-cell disease</measure>
    <time_frame>Baseline and yearly, up to 10 years</time_frame>
    <description>In addition to the incidence of the disease itself also possible complications will be reported in comparison to the preceding report (in case of the first report, only the prevalence will be reported as baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment of sickle-cell disease</measure>
    <time_frame>Baseline and yearly, up to 10 years</time_frame>
    <description>In addition to the incidence of the disease itself also the treatment received will be reported in comparison to the preceding report (in case of the first report, only the prevalence will be reported as baseline).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Sickle Cell Disease</arm_group_label>
    <description>Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with sickle cell disease being treated at participating centers that signed
        the informed consent form.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  current residency in either Germany, Austria or Switzerland

          -  sickle cell disease confirmed by hemoglobin analysis or molecular genetic analysis

               -  Homozygous sickle cell disease (HbSS)

               -  HbSC disease

               -  Sickle cell disease HbS / bThal

               -  Other, rare sickle cell syndromes such as HbS/OArab, HbS/HPFH, HbS/E, HbS/D
                  Punjab, HbS/C Harlem, HbC/S Antilles, HbS/Quebec-CHORI, HbA/S Oman, HbA/Jamaica
                  Plain

        Exclusion Criteria:

        - isolated heterozygous trait for HbS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Kunz, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Child and Adolescent Medicine, University Medical Center Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holger Cario, Prof. Dr.</last_name>
    <affiliation>University Hospital Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regine Grosse, Dr.</last_name>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Jarisch, Dr.</last_name>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Kulozik, Prof. Dr. PhD</last_name>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Lobitz, Dr. MSc</last_name>
    <affiliation>Kiniken der Stadt Köln gGmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joachim Kunz, Dr.</last_name>
    <phone>06221 56 4555</phone>
    <email>Joachim.Kunz@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Tagliaferri, Dr.</last_name>
    <phone>06221 56 4555</phone>
    <email>Laura.Tagliaferri@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Child and Adolescent Medicine, University Medical Center Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>69124</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Kunz, Dr.</last_name>
      <phone>06221 56 4555</phone>
      <email>Joachim.Kunz@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Laura Tagliaferri, Dr.</last_name>
      <phone>06221 56 4555</phone>
      <email>Laura.Tagliaferri@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sichelzellkrankheit.info/</url>
    <description>Official website of the Registry [German]</description>
  </link>
  <link>
    <url>http://www.awmf.org/uploads/tx_szleitlinien/025-016l_S2k_Sichelzellkrankheit_2014-12_verlaengert.pdf</url>
    <description>Sickle Cell Disease Guidelines, German language</description>
  </link>
  <reference>
    <citation>Lobitz S. Neugeborenenscreening auf Sichelzellkrankheiten in Deutschland. Kinder- und Jugendmedizin 2017;17(2):82-86 [German]</citation>
  </reference>
  <reference>
    <citation>Kunz JB, Cario H, Grosse R, Jarisch A, Lobitz S, Kulozik AE. The epidemiology of sickle cell disease in Germany following recent large-scale immigration. Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26550. Epub 2017 Apr 6.</citation>
    <PMID>28383793</PMID>
  </reference>
  <reference>
    <citation>Kunz JB, Awad S, Happich M, Muckenthaler L, Lindner M, Gramer G, Okun JG, Hoffmann GF, Bruckner T, Muckenthaler MU, Kulozik AE. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Ann Hematol. 2016 Feb;95(3):397-402. doi: 10.1007/s00277-015-2573-y. Epub 2015 Dec 12.</citation>
    <PMID>26658910</PMID>
  </reference>
  <reference>
    <citation>Grosse R, Lukacs Z, Cobos PN, Oyen F, Ehmen C, Muntau B, Timmann C, Noack B. The Prevalence of Sickle Cell Disease and Its Implication for Newborn Screening in Germany (Hamburg Metropolitan Area). Pediatr Blood Cancer. 2016 Jan;63(1):168-70. doi: 10.1002/pbc.25706. Epub 2015 Aug 14.</citation>
    <PMID>26275168</PMID>
  </reference>
  <reference>
    <citation>Frömmel C, Brose A, Klein J, Blankenstein O, Lobitz S. Newborn screening for sickle cell disease: technical and legal aspects of a German pilot study with 38,220 participants. Biomed Res Int. 2014;2014:695828. doi: 10.1155/2014/695828. Epub 2014 Jul 23.</citation>
    <PMID>25147811</PMID>
  </reference>
  <reference>
    <citation>Lobitz S, Frömmel C, Brose A, Klein J, Blankenstein O. Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany. Eur J Hum Genet. 2014 Aug;22(8):1051-3. doi: 10.1038/ejhg.2013.286. Epub 2014 Jan 8.</citation>
    <PMID>24398797</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Dr. Joachim Kunz</investigator_full_name>
    <investigator_title>Senior physician</investigator_title>
  </responsible_party>
  <keyword>Anemia, Sickle Cell</keyword>
  <keyword>Sickle Cell disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

